Jukka-Pekka Mecklin

Dr. Jukka-Pekka Mecklin


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 1993 in Science
Verified
Journal Article
Closed access
PDF file
LALauri A. Aaltonen
Lauri A. Aaltonen
PPPäivi Peltomäki
Päivi Peltomäki
FLFredrick S. Leach
Fredrick S. Leach
PSPertti Sistonen
Pertti Sistonen
LPLea Pylkkänen
Lea Pylkkänen
AEAl. Et
Al. Et
A predisposition to colorectal cancer is shown to be linked to markers on chromosome 2 in some families. Molecular features of "familial" cancers were compared with those of sporadic colon cancers. Neither the familial nor sporadic cancers showed loss of heterozygosity for chromosome 2 markers, and the incidence of mutations inKRAS,P53, andAPCwas similar in the two groups of tumors. Most of the familial cancers, however, had widespread alterations in short repeated DNA sequences, suggesting that numerous replication errors had occurred during tumor development. Thirteen percent of sporadic cancers had identical abnormalities and these cancers shared biologic properties with the familial cases. These data suggest a mechanism for familial tumorigenesis different from that mediated by classic tumor suppressor genes.

1 May 1991 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
PDF file
THThomas Hansen
Thomas Hansen
JMJukka-Pekka Mecklin
Jukka-Pekka Mecklin
PKP. Meera Khan
P. Meera Khan
HLH. T. Lynch
H. T. Lynch

1 May 2000 in Gastroenterology
Verified
Journal Article
Closed access
HJHeikki J. Järvinen
Heikki J. Järvinen
MAMarkku Aarnio
Markku Aarnio
HMHarri Mustonen
Harri Mustonen
KAKatja Aktan–Collan
Katja Aktan–Collan
LALauri A. Aaltonen
Lauri A. Aaltonen
JMJukka-Pekka Mecklin
Jukka-Pekka Mecklin

12 April 1999 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MAMarkku Aarnio
Markku Aarnio
RSRisto Sankila
Risto Sankila
EPEero Pukkala
Eero Pukkala
RSReijo Salovaara
Reijo Salovaara
LALauri A. Aaltonen
Lauri A. Aaltonen
HJHeikki J. Järvinen
Heikki J. Järvinen
Excessive incidence of various cancers is a challenging feature of the hereditary‐non‐polyposis‐colorectal‐cancer (HNPCC) syndrome. This study estimated the cancer incidences in HNPCC compared with the general population. Individuals in a cohort of 1763 members of 50 genetically diagnosed families were categorized according to their genetic status as mutation carriers, non‐carriers, or individuals at 50 or 25% risk of being a carrier. Incidences of cancers in these groups were compared with those in the Finnish population overall. In 360 mutation carriers, standardized incidence ratios (SIR) were significantly increased for colorectal [68; 95% confidence intervals (CI), 56 to 81], endometrial (62; 95% CI, 44 to 86), ovarian (13; 95% CI, 5.3 to 25), gastric (6.9; 95% CI, 3.6 to 12), biliary tract (9.1; 95% CI, 1.1 to 33), uro‐epithelial (7.6; 95% CI, 2.5 to 18) and kidney (4.7; 95% CI, 1 to 14) cancers and for central‐nervous‐system tumours (4.5; 95% CI, 1.2 to 12). The SIR increased with increasing likelihood of being a mutation carrier. The cumulative cancer incidences were 82, 60, 13 and 12% for colorectal, endometrial, gastric and ovarian cancers respectively. For other tumours associated with increased risk, corresponding incidences were below 4%. Interestingly, the incidence of endometrial cancer (60%) exceeded that for colorectal cancer in women (54%). The tumour spectrum associated with germline mutations of DNA‐mismatch‐repair genes involves 8 or more organ sites, suggesting a need to develop methods to screen for extra‐colonic cancer also. Int. J. Cancer 81:214–218, 1999.

21 May 1998 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LALauri A. Aaltonen
Lauri A. Aaltonen
RSReijo Salovaara
Reijo Salovaara
PKPaula Kristo
Paula Kristo
Federico CanzianFederico Canzian
Federico Canzian
AHAkseli Hemminki
Akseli Hemminki
EVErkki Valkamo
Erkki Valkamo
Genetic disorders that predispose people to colorectal cancer include the polyposis syndromes and hereditary nonpolyposis colorectal cancer. In contrast to the polyposis syndromes, hereditary nonpolyposis colorectal cancer lacks distinctive clinical features. However, a germ-line mutation of DNA mismatch-repair genes is a characteristic molecular feature of the disease. Since clinical screening of carriers of such mutations can help prevent cancer, it is important to devise strategies applicable to molecular screening for this disease. We prospectively screened tumor specimens obtained from 509 consecutive patients with colorectal adenocarcinomas for DNA replication errors, which are characteristic of hereditary colorectal cancers. These replication errors were detected through microsatellite-marker analyses of tumor DNA. DNA from normal tissue from the patients with replication errors was screened for germ-line mutations of the mismatch-repair genes MLH1 and MSH2. Among the 509 patients, 63 (12 percent) had replication errors. Specimens of normal tissue from 10 of these 63 patients had a germ-line mutation of MLH1 or MSH2. Of these 10 patients (2 percent of the 509 patients), 9 had a first-degree relative with endometrial or colorectal cancer, 7 were under 50 years of age, and 4 had had colorectal or endometrial cancer previously. In this series of patients with colorectal cancer in Finland, at least 2 percent had hereditary nonpolyposis colorectal cancer. We recommend testing for replication errors in all patients with colorectal cancer who meet one or more of the following criteria: a family history of colorectal or endometrial cancer, an age of less than 50 years, and a history of multiple colorectal or endometrial cancers. Patients found to have replication errors should undergo further analysis for germ-line mutations in DNA mismatch-repair genes.

1 December 2011 in The Lancet
Verified
Journal Article
Open access
John BurnJohn Burn
John Burn
AGAnne-Marie Gerdes
Anne-Marie Gerdes
FMFinlay Macrae
Finlay Macrae
JMJukka-Pekka Mecklin
Jukka-Pekka Mecklin
GMGabriela Moeslein
Gabriela Moeslein
DBD Timothy Bishop
D Timothy Bishop
Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo. In the CAPP2 randomised trial, carriers of Lynch syndrome were randomly assigned in a two-by-two factorial design to 600 mg aspirin or aspirin placebo or 30 g resistant starch or starch placebo, for up to 4 years. Randomisation was in blocks of 16 with provision for optional single-agent randomisation and extended postintervention double-blind follow-up; participants and investigators were masked to treatment allocation. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per protocol. This trial is registered, ISRCTN59521990. 861 participants were randomly assigned to aspirin or aspirin placebo. At a mean follow-up of 55·7 months, 48 participants had developed 53 primary colorectal cancers (18 of 427 randomly assigned to aspirin, 30 of 434 to aspirin placebo). Intention-to-treat analysis of time to first colorectal cancer showed a hazard ratio (HR) of 0·63 (95% CI 0·35-1·13, p=0·12). Poisson regression taking account of multiple primary events gave an incidence rate ratio (IRR) of 0·56 (95% CI 0·32-0·99, p=0·05). For participants completing 2 years of intervention (258 aspirin, 250 aspirin placebo), per-protocol analysis yielded an HR of 0·41 (0·19-0·86, p=0·02) and an IRR of 0·37 (0·18-0·78, p=0·008). No data for adverse events were available postintervention; during the intervention, adverse events did not differ between aspirin and placebo groups. 600 mg aspirin per day for a mean of 25 months substantially reduced cancer incidence after 55·7 months in carriers of hereditary colorectal cancer. Further studies are needed to establish the optimum dose and duration of aspirin treatment. European Union; Cancer Research UK; Bayer Corporation; National Starch and Chemical Co; UK Medical Research Council; Newcastle Hospitals trustees; Cancer Council of Victoria Australia; THRIPP South Africa; The Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma.